Biopharmaceutical product manufacturer 3SBio co-led the cancer therapy developer's series B round, which included WuXi Healthcare Ventures.
US-based oncology therapy developer Refuge Biotechnologies closed a $25m series B round yesterday co-led by biopharmaceutical product manufacturer 3SBio that featured a subsidiary of pharmaceutical research firm WuXi PharmaTech.
3SBio co-led the round with Sequoia Capital China, with participation from Sangel Capital, ShangBay Capital, DHVC, Oceanpine Healthcare and 3E Bioventures Capital. WuXi participated through its strategic investment arm, WuXi Healthcare Ventures.
Refuge Biotechnologies has developed an oncology therapeutics platform that utilises genetic alteration techniques called CRISPRi and CRISPa to target…
